Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NDI-219216 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on NDI-219216, a putative WRN inhibitor (Mar 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NDI-219216 | NDI 219216|NDI219216 | WRN Inhibitor 5 | Limited information is currently available on NDI-219216, a putative WRN inhibitor (Mar 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06898450 | Phase Ib/II | NDI-219216 | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients with Advanced Solid Tumors. | Recruiting | USA | IRL | FRA | ESP | AUS | 1 |